Status:
TERMINATED
Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors
Lead Sponsor:
Adaptimmune
Conditions:
Solid and Hematological Malignancies
Eligibility:
All Genders
18+ years
Brief Summary
Subjects who previously took part in an Adaptimmune study and received genetically changed T cells (including but not limited to MAGE-A10ᶜ⁷⁹⁶T and MAGE-A4ᶜ¹º³²T) are asked to take part in this long te...
Detailed Description
This is a non-therapeutic, multi-center, long-term follow-up (LTFU) study of subjects who have received lentivirus-mediated genetically engineered T Cell Receptors in an Adaptimmune sponsored clinical...
Eligibility Criteria
Inclusion
- Subjects must have received T cell receptor therapy in an Adaptimmune clinical study
- Subjects who have provided informed consent prior to their study participation
Exclusion
- Not applicable
Key Trial Info
Start Date :
February 28 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 24 2018
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT03391791
Start Date
February 28 2018
End Date
July 24 2018
Last Update
January 7 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
2
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
3
Princess Margaret Cancer Centr
Toronto, Ontario, Canada, M5G1X6